Sun Pharma launches ILUMYA for moderate-to-severe plaque psoriasis

01 Dec 2025 Evaluate

Sun Pharmaceutical Industries has launched its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis. ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years. 

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1808.90 -9.70 (-0.53%)
05-Dec-2025 12:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.90
Dr. Reddys Lab 1280.20
Cipla 1521.35
Zydus Lifesciences 933.70
Lupin 2100.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×